

Contents lists available at ScienceDirect

IF: 0.926

Asian Pacific Journal of Tropical Medicine

journal homepage:www.elsevier.com/locate/apjtm



Document heading

doi: 10.1016/S1995-7645(14)60347-3

Role of epidermal growth factor in pathogenesis of uterine leiomyomas

Chun Su¹, Mei Fan², Lin Lu³, Pei Li^{4*}

ARTICLE INFO

Article history:
Received 15 February 2015
Received in revised form 20 March 2015
Accepted 15 April 2015
Available online 20 May 2015

Keywords: HL-SMCs HM-SMCs Epidermal growth factor Uterine leiomyoma

ABSTRACT

Objective: To investigate the role of epidermal growth factor (EGF) in the pathogenesis of uterine leiomyomas. Methods: Human myometrial smooth muscle cells (HM-SMCs) and smooth muscle cells of human uterine leiomyomas (HL-SMCs) were separated from patients' specimens and cultured. After processed by EGF or PD98059 (inhibitor of MKK/MEK) +EGF, the proliferation rate of both SMCs was detected by BrdU method and the phosphorylation level of p44/42 mitogen-activated protein kinase (MAPK) was determined by Western-blot. After different processing time by EGF, the phosphorylation levels of p44/42 MAPK and AKT and p27 expression level in both SMCs were detected by Western-blot. Results: EGF could significantly promote HL-SMCs proliferation and PD98059 could inhibit this effect (P<0.05); besides, PD98059 could inhibit the increase of the phosphorylation level of p44/42 MAPK in both SMCs induced by EGF. When the processing time by EGF was over 15min, the phosphorylation levels of p44/42 MAPK and AKT in both SMCs decreased sharply and were close to zero; p27 expression in HM-SMCs raised significantly while the upregulation in HL-SMCs was little. Conclusions: EGF could not cause activation of EGFR because of the dephosphorylation of p44/42 MAPK and AKT in HL-SMCs, which caused p27 expression insufficiently and cell cycle dysregulation.

1. Introduction

Uterine leiomyomas were characterized by an increase in smooth muscle cells (SMCs) proliferation and excessive deposition of extracellular matrix proteins, primarily collagens type I and III[1,2]. Formation of leiomyomas was viewed as a multistep process, with involvement of ovarian steroid hormones, cytokines and growth factors. Steroid hormones induced mitogenic effects directly through their receptors or by regulating expression of growth factors

such as epidermal growth factor (EGF) and platelet derived growth factor (PDGF) and their respective receptors[3]. Mitogen-activated protein kinase (MAPK) signal pathway was the main transduction path which can regulate cell growth, proliferation and differentiation and so on[4–6]. Many tumors, through autocrine or paracrine modes, could produce EGF which could combine with EGFR to form a dimer, activating their inherent tyrosine kinase and consequently activating the signal pathways in cells (such as MAPK pathway)[7,8]. In the study, human myometrial smooth muscle cells (HM-SMCs) and smooth muscle cells of human uterine leiomyomas (HL-SMCs) were processed by EGF, and then we investigated the trends of the

phosphorylation levels of p44/42 MAPK in order to explore the role

of EGF in the pathogenesis of uterine leiomyomas.

¹Department of Gynaecology and Obstetrics, The Fifth Affiliated Hospital of Zhengzhou University, Kangfu Qian Street No.3, 450052, Zhengzhou, China

²Department of Ultrasound , The First Affiliated Hospital of Zhengzhou University, Jianshe Dong Street No.1, 450052, Zhengzhou, China

Department of Ultrasound, The Third Affiliated Hospital of Zhengzhou University, Kangfu Qian Street No.7, 450052, Zhengzhou, China

⁴Department of Pathophysiology, Zhengzhou University, Zhengzhou 450001, China

^{*}Corresponding author: Pei Li, Department of Pathophysiology, Zhengzhou University, Science Avenue No.100, High-Tech Zone, 450001, Zhengzhou, China. Tel: 13653805038

E-mail: lip2006@163.com

Foundation project: The study was supported by Program for New Century Excellent Talents in University (NCET-11-0949).

2. Materials and methods

2.1. Cultivation of SMCs

10 human uterine leiomyomas specimens and 10 normal myometrium specimens from cervical intraepithelial neoplasia patients undergone the total hysterectomy were collected after informed consent. Then the uterine leiomyomas and normal myometrium were separated and cut into pieces. Then the pieces were placed into 25 cm³ culture flask with 0.1% collagenase I in 5% CO_2 incubator at 37 °C for 5-6 h. After the pieces were digested into single cells, they were centrifuged at 1 000 rpm for 8min and beat repeatedly with dulbecco's modified eagle medium (DMEM) for adjusting concentration at 1×10^5 cells/mL. After that, the cells were incubated in 5% CO_2 incubator at 37 °C [9].

2.2. Bromodeoxyuridine (BrdU) method

HM-SMCs and HL-SMCs in logarithmic phase were plated in 96-well plate at 5×10^4 cells/mL and grew to confluence. Then the cells were processed, the processing design was as followed: a: control cells in DMEM; b: cells in DMEM with EGF (100 ng/mL, for 24 h); c: cells pretreated with 20 μ M PD98059 (inhibitor of MKK/MEK, for 1h) in DMEM + EGF (100 ng/mL, for 24 h).

When the processing time by EGF was left 1 hour, the medium was switched to culture medium containing 10 $\,\mu$ M BrdU and cells were incubated for 1 hour. BruU incorporation rate was measured by using a microplate reader. Three independent experiments were performed, and each assay was carried out in triplicate.

2.3. Western-blot

After being starved for 24h, the cells were processed by 100 ng/mL EGF for 15 min; besides, PD98059 was added before EGF in another group and the experimental design in detail was according to 2.2. After the cells were lysed and went through the incubation of primary antibody and secondary antibody, the grey value of target protein was measured by Quantity One software.

In order to observe the trends of the phosphorylation levels of p44/42 MAPK and AKT and expression level of p27, both SMCs were processed by 100 ng/mL EGF for 15min, 30min, 60min, 120min and 240min, respectively. And then, the cells were collected at different time points. The target proteins expression level were detected and measured.

2.4. Statistical analysis

SPSS18.0 was used for statistical analysis, all the data were showed by mean±SD. Statistical analysis was performed using One-Way ANOVA with Dunnett's multiple comparisons test. *P*<0.05 was considered to be statistical significance.

3. Results

3.1. Effect of EGF on phosphorylation of p44/42 MAPK

After the processing by EGF, the phosphorylation level of p44/42 MAPK in both SMCs increased significantly (P<0.05), and it was remarkably higher in HM-SMCs than in HL-SMCs (P<0.05) (Figure 1, Table 1).




Figure 1. Influence of EGF on phosphorylation level of p44/42 MAPK in HM-SMCs and HL-SMCs

3.2. PD98059's effect on cell proliferation and p44/42 MAPK phosphorylation induced by EGF

Figure 2a showed that EGF could significantly promote the proliferation only in HL-SMCs (*P*<0.05). However, PD98059 could inhibit this promotion effect (*P*<0.05). Besides, PD98059 could inhibit the increase of the phosphorylation level of p44/42 MAPK in both cells induced by EGF (Figure 2b).




Figure 2. Influence of PD98059 on phosphorylation of p44/42 MAPK and proliferation rate in both SMCs.

Note: *: compared with control group, P<0.05; #: compared with EGF group, P<0.05.

Table 1
Relative expression level of p44/42MAPK and p-p44/42MAPK protein before and after the treatment of EGF.

	HM-SMCs		HL-SMCs	
	EGF(-)	EGF(+)	EGF(-)	EGF(+)
p44/42MAPK	1.38±0.19	1.43±0.21	1.41±0.25	1.47±0.24
p-p44/42MAPK	0.28±0.06	0 .90±0.14 [#]	0.22±0.05	0.42±0.09*#

Note: *After the same treatment, in HM-SMCs vs in HL-SMCs, P<0.05; *in the same SMCs, before treatment vs. after treatment, P<0.05.

3.3. EGF affected phosphorylation of p44/42 MAPK and AKT and p27 expression

When the processing time of EGF was over 15min, the phosphorylation level of p44/42 MAPK and AKT in both SMCs decreased. The decreasing amplitude in HL-SMCs was more obvious than that in HM-SMCs, the phosphorylation rate in HL-SMCs was close to 0 (Figure 3). P27 expression level in HM-SMCs induced by EGF increased significantly while the increase in HL-SMCs was little.




Figure 3. Phosphorylation level of p44/42 MAPK and AKT and expression level of p27 in HM-SMCs and HL-SMCs after being processed by EGF.

4. Discussion

EGF was a kind of strong mitogen, which could stimulate the division and proliferation of multi-type cells and participated in the regulation of multiple physiological and pathological functions[10,11]. In the study, EGF obviously raised the phosphorylation level of p44/42 MAPK in both SMCs and cell proliferation in HL-SMCs, while PD98059 could inhibit this up-regulation. These results implied that p44/42 MAPK, as the downstream signal factor of EGFR-MEK signal pathway, played an important role in the regulation of DNA synthesis in HL-SMCs[12,13]. With the processing time passed, the inhibitory effect on the activation of p44/42 MAPK in HL-SMCs was becoming more and more serious, but this inhibitory effect in HM-SMCs was quite weak.

A role of EGF in leiomyoma growth was supported by the fact that the selective EGF-R blocker AG1478 was able to block leiomyoma cell proliferation[14]. Mesquita *et al*[15] firstly proved in their study that reactive oxygen species (ROS) produced by NAPDH oxidase system of LSMCs participated in the regulation of transduction pathway of growth factor signals, and they thought LSMCs produce ROS in response to EGF. Our study showed PD98059 could inhibit DNA synthesis in HL-SMCs as well as the increase of p44/42 MAPK phosphorylation level induced by EGF in both SMCs[16]. In the study of molecular mechanism by which genistein induced the

excessive proliferation of uterine leiomyoma cells, Di *et al*[9] found that after the processing of genistein, the trans-activation of estrogen receptor, the expression of mRNA of estrogen responsive gene, progesterone receptor, IGF-1 all increased while the use of PD98059 can inhibit the up regulation and the excessive proliferation of uterine leiomyoma cells caused by genistein. In the study, after the processing of EGF, the expression level of p27 in HM-SMCs was drastic and steady while it rose a little in HL-SMCs. Therefore, we speculated that in HM-SMCs, through promoting the activation of p44/42 MAPK sharply and steadily, the expression level of p27 raised sufficiently and thus ensured the cell cycle to function well[17]. But in HL-SMCs, EGF led the phosphorylation level of p44/42 MAPK or AKT to be close to 0, which impossibly led to the abovementioned occurrences happened. Eventually, the cell cycle could not function well in HL-SMCs[18–20].

Currently, there are many therapies inhibit the development of tumors through preventing the activation of EGFR[21–24]. Though we certified the role of EGF in the pathogenesis of uterine leiomyomas *in vitro*, there is a needing for testifying its role *in vivo*.

In summary, EGF could not cause the activation of EGFR because of the dephosphorylation of p44/42 MAPK or AKT in HL-SMCs, which caused p27 expression insufficiently and cell cycle dysregulation.

Conflict of interest statement

We declare that we have no conflict of interest.

References

- Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science 2005; 308(5728):1589-1592.
- [2] Leppert PC, Baginski T, Prupas C, Catherino WH, Pletcher S, Segars JH. Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium. *Fertil Steril* 2004; 82(suppl 3): 1182-1187.
- [3] Barbarisi A, Petillo O, Di Lieto A, Melone MA, Margarucci S, Cannas M, et al. 17-Beta estradiol elicits an autocrine leiomyoma cell proliferation: evidence for a stimulation of protein kinase-dependent pathway. *J Cell Physiol* 2001; 186(3):414-424.
- [4] Bai HW, Badaboina S, Park CH, Choi BY, Na YH, Chung BY. Centipedegrass extract induces apoptosis through the activation of caspases and the downregulation of PI3K/Akt and MAPK phosphorylation in leukemia cells. *Int J Mol Med* 2015; 35(2): 511-518.
- [5] Lei YY, Wang WJ, Mei JH, Wang CL. Mitogen-activated protein kinase singal transduction in solid tumors. Asian Pac J Cancer Prev 2014; 15(20): 8539-8548.

- [6] Irazoqui AP, Boland RL, Buitrago CG. Actions of 1,25(OH)2-vitamin D3 on the cellular cycle depend on VDR and p38 MAPK in skeletal muscle cells. J Mol Endocrinol 2014; 53(3): 331-343.
- [7] Sangrar W, Shi C, Mullins G, LeBrun D, Ingalls B, Greer PA. Amplified Ras-MAPK signal states correlate with accelerated EGFR internalization, cytostasis and delayed HER2 tumor onset in Fer-difficient model systems. Oncogene 2014 Oct 27.
- [8] Shi YH, Tuokan T, Lin C, Chang H. Aquaporin 8 involvement in human cervical cancer SiHa migration via the EGFR-Erk1/2 pathway. *Asian Pac J Cancer Prev* 2014; 15(15): 6391-6395.
- [9] Di X, Yu L, Moore AB, Castro L, Zheng X, Hermon T, et al. A low concentration of genistein induces estrogen receptoralpha and insulinlike growth factor-I receptor interactions and proliferation in uterine leiomyoma cells. *Hum Reprod* 2008; 23(8): 1873-1883.
- [10]Arkhipov A, Shan Y, Kim ET, Shaw DE. Membrane interaction of bound ligands contributes to the negative binding cooperativity of the EGF receptor. *PLoS Comput Biol* 2014; **10**(7): e1003742.
- [11] Trapani V, Arduini D, Luongo F, Wolf FI. EGF stimulate Mg²⁺ influx in mammary epithelial cells. *Biocehm Biophys Res Commun* 2014; 454(4): 572-575.
- [12]Bae GY, Choi SJ, Lee JS, Jo J, Lee J, Kim J, et al. Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer. *Oncotarget* 2013; 4(12): 2512-2522.
- [13]Shih YP, Takada Y, Lo SH. Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells. *Mol Cancer Res* 2012; 10(1): 34-39.
- [14]Shushan A, Rojansky N, Laufer N, Klein BY, Shlomai Z, Levitzki R, et al. The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth. *Hum Reprod* 2004; **19**(9): 1957-1967.
- [15]Fernando S. Mesquita, Summer N. Dyer, Daniel A. Heinrich, et al. Reactive oxygen species mediate mitogenic growth factor signaling pathways in human leiomyoma smooth muscle cells. *Biol Reprod* 2010; 82(2): 341-351.

- [16]Stamatiou R, Paraskeva E, Vasilaki A, Mylonis I, Molyvdas PA, Gourgoulianis K, et al. Long-term exposure to muscarinic agonists decreases expression of contractile proteins and responsiveness of rabbit tracheal smooth muscle cells. BMC Pulm Med 2014; 14: 39.
- [17]Gui Y, Zheng XL. Epidermal growth factor induction of phenotypedependent cell cycle arrest in vascular smooth muscle cells in through the mitogen-activated protein kinase pathway. J Biol Chem 2003; 278(52): 53017-53025.
- [18]Jansen C, Ihse I, Axelson. Epidermal growth factor induces increased mucosal thickness of the small intestine in mouse. European Surg Res Europaische chirurgische Forschung 1997; 29(6): 447-454.
- [19]Berlanga-Acosta J, Playford RJ, Mandir N, Goodlad RA. Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats. *Gut* 2001; 48(6): 803-807.
- [20]Villanueva D, Mccants D, Nielsen HC. Effects of epidermal growth factor (EGF) on the development of EGF-receptor (EGF-R) binding in fetal rabbit lung organ culture. *Pediatr Pulmonol* 2009; 29(1): 27-33.
- [21]Bhattacharyya S, Patel N, Wei L, Riffle LA, Kalen JD, Hill GC, et al. Synthesis and biological evaluation of panituumab-IRDye800 conjugate as a fluorescence imaging probe for EGFR-expressing cancers. *Medchemcomm* 2014; 5(9): 1337-1346.
- [22] Asbagh LA, Vazquez I, Vecchione L, Budinska E, De Vriendt V, Baietti MF, et al. The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling. *Oncotarget* 2014; 5(20): 10070-10083.
- [23]Soni P, Husain N, Awasthi R, Chandra A, Ojha BK, Gupta RK. Revisiting epidermal growth factor receptor in glioblastoma multiforme: does it play a role in response to therapy? *Indian J Pathol Microbiol* 2014; 57(3): 390-395.
- [24] Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, et al. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. Br J Cancer 2014; 111(6): 1065-1071.